404
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review

, , , &
Pages 835-847 | Received 12 Aug 2019, Accepted 30 Nov 2020, Published online: 29 Dec 2020

References

  • BUIST AS. The US Lung Health Study. Respirology. 1997;2:303–307.
  • Behrakis PKVC, Papadakis SE. eds. Tobacco cessation guidelines for high risk populations. 2017. Tob-G Project. accessed 2020 Nov 20; Available from: http://tob-g.eu/tobacco-cessation-guidelines-for-high-risk-populations-2/
  • Tønnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013;22:37–43.
  • Global Initiative for Chronic Obstructive Pulmonary Disease. 2019. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. accessed 2020 Sep.  Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
  • Nizet TA, van den Elshout FJ, Heijdra YF, et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005;(127):1904–1910.
  • Gratziou C, Florou A, Ischaki E, et al. Smoking cessation effectiveness in smokers with COPD and asthma under real life conditions. Respir Med. 2014;108:577–583.
  • Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001;119:1365–1370.
  • Trofor AC, Man MA, Marginean C, et al. Smoking cessation for free: outcomes of a study of three Romanian clinics. Open Med (Wars). 2016;11:605–610.
  • Trofor AC, Papadakis S, Lotrean L, et al. Tobacco treatment guideline for high risk groups: a pilot study in patients with chronic obstructive pulmonary disease. Tob Induc Dis. 2018;16:13.
  • Fiore MC. Treating tobacco use and dependence: an introduction to the US public health service clinical practice guideline. Respir Care. 2000;45:1196–1199.
  • Fiore MC, Hatsukami DK, Baker TB. Effective tobacco dependence treatment. JAMA. 2002;(288):1768–1771.
  • Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;18(4):CD000165.
  • Fiore MCJC, Baker TB, et al. Treating tobacco use and dependence. Clinical practice guideline 2008 update. Rockville, MD, US: Department of Health and Human Services; 2008.
  • Al SDe. American college of chest physicians tobacco-dependence treatment tool kit. 3rd Edition ed. 2010. Glenville, Illinois: American College of Chest Physician. Available from: https://foundation.chestnet.org/wp-content/uploads/2020/04/Tobacco-Dependence-Toolkit.pdf
  • van Eerd EA, van der Meer RM, van Schayck OC, et al. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;2016(8):CD010744.
  • van Eerd EA, van Rossem CR, Spigt MG, et al. Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco smoking. Respiration. 2015;90:211–219.
  • The health consequences of smoking: nicotine addiction: a report of the Surgeon General. 1988. Available from: https://profiles.nlm.nih.gov/spotlight/nn/catalog/nlm:nlmuid-101584932X423-doc
  • Hall SM, Herning RI, Jones RT, et al. Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther. 1984;35:810–814.
  • Henningfield JE. Pharmacologic basis and treatment of cigarette smoking. J Clin Psychiatry. 1984;45:24–34.
  • Henningfield JE, Goldberg SR. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav. 1983;19:1021–1026.
  • Harvey DM, Yasar S, Heishman SJ, et al. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl). 2004;175:134–142.
  • Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4(4):CD013308. doi:10.1002/14651858.CD013308.
  • Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89:392–399.
  • Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97:505–516.
  • Wadgave U, Nagesh L. Nicotine replacement therapy: an overview. Int J Health Sci (Qassim). 2016;10:425–435.
  • Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA. 1994;272:1497–1505.
  • Scanlon PD, Connett JE, Waller LA, et al. Lung health study research G. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The lung health study. Am J Respir Crit Care Med. 2000;161:381–390.
  • Murray RP, Gerald LB, Lindgren PG, et al. Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the lung health study. Prev Med. 2000;30:392–400.
  • Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. CHEST. 2006;130:334–342.
  • Lindson-Hawley N, Coleman T, Docherty G, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. Trials. 2014;15:296.
  • Preloading I. Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial. BMJ. 2018;361:k2164–k2164.
  • Przulj D, Wehbe L, McRobbie H, et al. Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods. Addiction. 2019;114:515–522.
  • Hartmann‐Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):CD000146.
  • Haokip HR, Kumar DR, Singh Rawat DV, et al. Efficacy of standard nicotine replacement therapy (NRT) versus video-assisted nurse-led NRT on tobacco cessation: A randomized controlled pilot trial. Clin Epidemiol Global Health. 2020;9:141–146.
  • Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J. 2005;26:242–248.
  • Rigotti NA. Smoking cessation in patients with respiratory disease: existing treatments and future directions. Lancet Respir Med. 2013;1:241–250.
  • Strassmann R, Bausch B, Spaar A, et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009;34:634–640.
  • Jimenez-Ruiz CA, Fagerstrom KO. Smoking cessation treatment for COPD smokers: the role of pharmacological interventions. Monaldi Arch Chest Dis. 2013;79:27–32.
  • Ellerbeck EF, Nollen N, Hutcheson TD, et al. Effect of long-term nicotine replacement therapy vs standard smoking cessation for smokers with chronic lung disease: a randomized clinical trial long-term nicotine replacement vs standard smoking cessation in chronic lung disease long-term nicotine replacement vs standard smoking cessation in chronic lung disease. JAMA Network Open. 2018;1:e181843–e181843.
  • Hagens P, Pieterse M, van der Valk P. Effectiveness of intensive smoking reduction counselling plus combination nicotine replacement therapy in promoting long-term abstinence in patients with chronic obstructive pulmonary disease not ready to quit smoking: protocol of the REDUQ trial. Contemp Clin Trials Commun. 2017;8:248–257.
  • Hashimoto R, Tomioka H, Wada T, et al. Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. Respir Investig. 2020;58:387–394.
  • Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178:622–631.
  • Giulietti F, Filipponi A, Rosettani G, et al. Pharmacological approach to smoking cessation: an updated review for daily clinical practice. High Blood Press Cardiovasc Prev. 2020;27:349–362.
  • McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38:394–402.
  • Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;2014(1):CD000031.
  • Sterling LH, Windle SB, Filion KB, et al. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;22;5(2):e002849. doi:10.1161/JAHA.115.002849
  • Gonzales D, Rennard SI, Nides M, et al. Varenicline phase 3 study group ft. varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA. 2006;296:47–55.
  • Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77:324–336.
  • Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial nicotine patch, varenicline, or combination therapy for smoking cessation nicotine patch, varenicline, or combination therapy for smoking cessation. JAMA. 2016;315:371–379.
  • Agboola SA, Coleman T, McNeill A, et al. Abstinence and relapse among smokers who use varenicline in a quit attempt—a pooled analysis of randomized controlled trials. Addiction. 2015;110:1182–1193.
  • Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591–599.
  • Jiménez-Ruiz CARPA, Cicero Guerrero A, Lopez Gonzalez G. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14:1035–1039.
  • Sansores RH, Ramírez-Venegas A, Arellano-Rocha R, et al. Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study. Ther Adv Respir Dis. 2016;10:383–390.
  • Hernández Zenteno RJ, Lara DF, Venegas AR, et al. Varenicline for long term smoking cessation in patients with COPD. Pulm Pharmacol Ther. 2018;53:116–120.
  • Politis A, Ioannidis V, Gourgoulianis KI, et al. Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial. Chron Respir Dis. 2018;15:146–156.
  • Hilberink SR, Jacobs JE, Breteler MH, et al. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Educ Couns. 2011;83:120–124.
  • Tutka P, Vinnikov D, Courtney RJ, et al. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction. 2019;114(11):1951–1969. doi:10.1111/add.14721. Epub 2019 Jul 19.
  • Gómez-Coronado N, Walker AJ, Berk M, et al. Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy. 2018;38:235–258.
  • Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014;371:2353–2362.
  • West R, Zatonski W, Cedzynska M, et al. Placebo-Controlled Trial of Cytisine for Smoking Cessation. N Engl J Med. 2011;365:1193–1200.
  • Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998;158:2035–2039.
  • Herman AI, Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep. 2010;12:433–440.
  • Kotz D, Wesseling G, Huibers MJ, et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J. 2009;33:754–762.
  • Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;2004(3);CD000058.
  • Marlow SP, Stoller JK. Smoking Cessation. Respir Care. 2003;48:1238–1256.
  • Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2000;(4):CD002849.
  • Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;1998(2):CD001009.
  • Nagano T, Katsurada M, Yasuda Y, et al. Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials. Ther Adv Respir Dis. 2019;13:1753466619875925.
  • Prado E, Maes M, Piccoli LG, et al. N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study. Redox Rep. 2015;20:215–222.
  • Barua RS, Rigotti NA, Benowitz NL, et al. ACC expert consensus decision pathway on tobacco cessation treatment: a report of the american college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72:3332–3365.
  • Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–637.
  • Kyriakos CN, Filippidis FT, Hitchman S, et al. Consortium E-P. characteristics and correlates of electronic cigarette product attributes and undesirable events during e-cigarette use in six countries of the EUREST-PLUS ITC Europe surveys. Tob Induc Dis. 2018;16:A1–A1.
  • Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.